Immunovant shares have gained about 3.6% over the past month, outperforming the S&P 500, following a fourth-quarter 2026 net loss of 73 cents per share that was wider than the Zacks Consensus Estimate of a 60-cent loss. Research and development expenses climbed 51.9% to $142.3 million, driven by clinical activities for IMVT-1402 and $39 million in costs tied to the discontinuation of batoclimab. Cash and cash equivalents stood at approximately $902.1 million as of March 31, 2026, which the company expects will fund operations through the commercial launch of IMVT-1402 for GD. Analysts have been revising estimates downward, and the stock currently carries a Zacks Rank #3, or Hold, with an aggregate VGM Score of F.
Immunovant IncWider-than-expected loss and rising R&D costs are negative, but stock rose 3.6% over the past month, possibly due to other factors; net effect unclear.
TG Therapeutics Inc